The FDA’s Role in the Development of Bioterrorist Countermeasures

DSpace/Manakin Repository

. . . . . .

Title:	The FDA’s Role in the Development of Bioterrorist Countermeasures
Author:	Guerra, Marcelo
Citation:	The FDA’s Role in the Development of Bioterrorist Countermeasures (2004 Third Year Paper)
Full Text & Related Files:	Guerro.pdf (309.1Kb; PDF) Guerro.rtf (302.7Kb; RTF file) Guerro.html (214.0Kb; HTML)
Abstract:	As the agency that approves drug products used to treat bioterrorist diseases, the FDA plays a significant role in the domestic preparation against a bioterrorist attack. The changes that occurred at the agency in response the AIDS and cancer crises of the 1980’s have served as a blueprint for the changes made in response to the terrorist threat. These changes, often desirable but sometimes not, push even further the agency’s role as a collaborator in drug development. The paper investigates the threat of a biological weapon attack and the changes to the drug approval process that this threat has prompted.
Terms of Use:	This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page:	http://nrs.harvard.edu/urn-3:HUL.InstRepos:10015278